• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies

  • Print
  • Share
  • E-mail

Post-Approval Studies

  • In January 2005, the oversight responsibility of the Post-Approval Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH).
  • The CDRH Post-Approval Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated as a condition of approval of a premarket approval (PMA) application, protocol development product (PDP) application, or humanitarian device exemption (HDE) application. The program helps ensure that well-designed post-approval studies (PAS) are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated, internal tracking system that efficiently identifies the reporting status of active PAS studies ordered since January 1, 2005 based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all PAS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each PAS. The webpage displays general information regarding each PAS, as well as the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant's reporting status for each submission due.


Contact Information

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD

Phone: (301) 796-6134
Fax: (301) 847-8140

Show All Studies
Suggest Enhancement / Report Issue | Export to ExcelExport to Excel
Application Number P110002
Current Protocol Accepted 06/03/2014
Study Name OSB Lead-Enhanced Surveillance System
Study Status Progress Adequate
General Study Protocol Parameters
Study Design Enhanced Surveillance
Study involve follow-up of premarket cohort (Y/N) No
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description A 10-year Enhanced Surveillance Study (ESS) of the Mobi-C®

Cervical Disc Prosthesis to fully characterize adverse   show the rest ...
Study Population Description All patients who are implanted with the device

The data on AEs will be collected by   show the rest ...
Sample Size N/A
Data Collection All adverse Events will be reported including HO, neurological

complications, subsequent surgeries and etc. The data   show the rest ...
Followup Visits and Length of Followup 10 years

OSB Lead-Enhanced Surveillance System Schedule

Report Schedule
Date Due
FDA Receipt
Reporting Status
six month report 02/05/2014 02/04/2014 On Time
one year report 08/07/2014 08/07/2014 On Time
18 month report 02/05/2015 02/09/2015 Overdue/Received
two year report 08/07/2015 08/10/2015 Overdue/Received
three year report 08/06/2016 08/08/2016 Overdue/Received
four year report 08/06/2017    
five year report 08/06/2018    
six year report 08/07/2019    
seven year report 08/07/2020    
eight year report 08/07/2021    
nine year report 08/07/2022    
ten year/final report 08/07/2023    

Show All Studies